Acta Obstetricia Et Gynecologica Scandinavica · 2007 · 150 citations · 6 references
MedicineMaternal HealthObstetricsHigh-risk PregnancyMaternal-fetal MedicinePerinatal EpidemiologyAntenatal Risk AssessmentPerinatal Risk FactorsPregnancyPregnancy ImagingPrenatal DevelopmentPrenatal Risk AssessmentMagnetic ResonanceParamagnetic Contrast AgentsPharmaceutical Exposure During PregnancyPregnancy Drug ExposurePrenatal Chemical ExposurePrenatal Drug ExposureTeratogenic Risk AssessmentTeratogenicity Risk Assessment
BACKGROUND: Gadolinium derivatives are ionic paramagnetic contrast agents used to enhance magnetic resonance images, labeled as a pregnancy category C by the Food and Drug Administration because of a lack of epidemiological studies concerning first-trimester exposure. METHODS: Prospective cohort study to determine whether gadolinium derivatives exposure in periconceptional period is a risk factor for pregnancy or fetal development. RESULTS: We report the outcome of 26 pregnant women exposed to gadolinium derivatives in the first trimester without adverse effect on pregnancy and neonatal outcome. CONCLUSIONS: Currently, this study represents the only prospective investigation of gadolinium derivatives in pregnancy, but more data are necessary to exclude a teratogenic risk.
6
Normal placenta: gadolinium-enhanced dynamic MR imaging.
Hani B. Marcos, Richard C. Semelka, S Worawattanakul · Radiology · 1997 · 144 citations
Medicine, Obstetrics, Radiology +17
Gadolinium-DTPA transplacental transfer and distribution in fetal tissue in rabbits.
Zina Novak, Amy S. Thurmond, Penny L. Ross et al. · PubMed · 1993 · 64 citations